AE adds Roche’s CREAD trial to its Clinical Trials Watch
Monday 27 February 2017
In September 2016, Alzheimer Europe (AE) launched the Clinical Trials Watch (CTW) – a service with up-to-date, accessible information on clinical trials. During February 2016, AE added another clinical trial to the service: Hoffmann-La Roche’s CREAD study. The study is investigating the drug Crenezumab (a monoclonal antibody that specifically recognises Aβ), as a treatment for Alzheimer's disease (AD). The study is active in 11 EU countries, will include around 750 participants worldwide and is expected to run until 2021.
The purpose of the CTW is to provide accessible and up-to-date information on clinical trials (i.e. studies) that are investigating drugs for AD and/or dementia. We hope that this information is useful to affected people, their families, carers and anyone with an interest in dementia research. This is not an exhaustive resource of information. It contains information about clinical trials that are:
- Currently recruiting participants
- Conducted in at least two European countries
- In phase III - in these trials the drug/treatment is tested in large groups of people, involving from several hundred to several thousand participants. These trials are conducted to provide stronger evidence of the effectiveness and safety of the new drug / treatment.
Further information about the CTW is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch
Further information about the CREAD study is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch/CREAD-study
Please note this information should not be interpreted as a recommendation to use a treatment, nor to participate in a study.
For more information about the CTW please contact Cindy Birck, Project Officer: email@example.com